Clinical Trial

Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

Study acronym: ANTONIO
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators hypothesize that atezolizumab will improve the prognosis of patients with stage III dMMR CRC ineligible for or refusing oxaliplatin-based adjuvant chemotherapy compared to SOC and that these could therefore be promising therapeutic options.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-11-02; most recent amendment 2025-06-12.
Status change: Recruiting → Active, Not Recruiting 2024-12-11
Status change: Not Yet Recruiting → Recruiting 2022-01-10
Trial Details
NCT Number NCT05118724
Lead Sponsor AIO-Studien-gGmbH
Collaborators: Roche Pharma AG, Immodulon Therapeutics Ltd
Conditions Colorectal Cancer
Enrollment 80 participants
Start Date 2021-12-10
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2025-06-15